Skip to Main Content

WASHINGTON — Drug company lobbyists are pushing lawmakers to include in the forthcoming appropriations package two small changes to Medicare that could help them reap bigger profits from the federal program.

Johnson & Johnson, Amgen, and Genentech, the makers of several of the most popular “biologic” drugs, are lobbying Republicans to add a provision that ensures that one Medicare program doesn’t pay more for newer “biosimilar” drugs than it does for their products, according to several congressional aides and lobbyists.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED